Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
MasterCard
MA
CN Stock MarketDetailed Quotes
000078 Shenzhen Neptunus Bioengineering
- 2.27
- +0.02+0.89%
Market Closed Apr 30 15:00 CST
5.97BMarket Cap-4.92P/E (TTM)
2.30High2.24Low136.30KlotVolume2.24Open2.25Pre Close31.01MTurnover0.52%Turnover RatioLossP/E (Static)2.63BShares3.1952wk High3.29P/B5.96BFloat Cap2.0752wk Low2.48Limit Up2.63BShs Float14.30Historical High2.03Limit Down2.67%Amplitude0.40Historical Low--Dividend TTM2.27Avg Price60.78KlotAsk--Div YieldTTM100Lot Size72.73KlotBid
Shenzhen Neptunus Bioengineering News
Kaiwang Biotech: Announcement on the 2024 write-off of bad debts and preparation for asset impairment
Neptune Biotech: 2024 Annual Financial Report
Kaiwang Biotech: Audit Committee Report on the 2024 Performance Evaluation Report of Accounting Firms and Report on the Performance of Supervisory Duties
Kaiwang Biotech: Report on the 2024 Assessment Report on the Performance Status of Accounting Firms
Haiwang Biotech: Special instructions on the elimination of internal control highlights in the first half of the 2024 fiscal year of Shenzhen Haiwang Biotechnology Co., Ltd. in this issue
Neptune Biotech: Notice of Annual General Meeting of Shareholders
Haiwang Biotech: Announcement of Resolutions of the 2025 First Extraordinary General Meeting of Shareholders
Neptune Biotech: Announcement on new cumulative lawsuits and arbitration
Haiwang Biotech: Legal Opinions of Beijing Deheng (Shenzhen) Law Firm on the 2025 First Extraordinary General Meeting of Shareholders of Shenzhen Haiwang Biotech Co., Ltd.
Haiwang Biotech: Announcement on the Notice of Convening the First Extraordinary General Meeting of Shareholders in 2025
Neptune Biotech: Announcement on the implementation of guarantees for wholly-owned subsidiaries
Haiwang Biotech: Legal Opinions of Beijing Deheng (Shenzhen) Law Firm on the 2024 Fourth Extraordinary General Meeting of Shareholders of Shenzhen Haiwang Biotech Co., Ltd.
Haiwang Biotech: Announcement of Resolutions of the 2024 Fourth Extraordinary General Meeting of Shareholders
Neptune Biotech: Announcement on the extension of the company\'s controlling shareholder\'s commitment to avoid competition in the same industry
Haiwang Biotech: Announcement on Additional Provisional Proposals for the 2024 Fourth Extraordinary General Meeting of Shareholders and Supplementary Notice to the Shareholders\' Meeting
Haiwang Biotech: Announcement on the Notice of Convening the Fourth Extraordinary General Meeting of Shareholders in 2024
Neptune Biotech: Announcement on cumulative lawsuits and arbitration
Neptune Biotech: Announcement on completing the registration of industrial and commercial changes
Haiwang Biotech: Announcement on not holding a shareholders\' meeting
Haiwang Biotech: Legal Opinions of Beijing Deheng (Shenzhen) Law Firm on the 2024 Third Extraordinary General Meeting of Shareholders of Shenzhen Haiwang Biotech Co., Ltd.
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts